Cellular actions of somatostatin on rat periaqueductal grey neurons in vitro

Mark Connor, Elena E. Bagley, Vanessa A. Mitchell, Susan Ingram, MacDonald J. Christie, Patrick P A Humphrey, Christopher W. Vaughan

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Functional studies indicate that the midbrain periaqueductal grey (PAG) is involved in the analgesic actions of somatostatin; however, the cellular actions of somatostatin in this brain region are unknown. In the present study, whole-cell patch clamp recordings were made from rat PAG neurons in vitro. In 93% of acutely isolated neurons, somatostatin inhibited Ca 2+-channel currents. This effect was mimicked by the sst-2 selective agonist BIM-23027, but not by the sst-1 and sst-5 selective agonists CH-275 and L-362855. In brain slices, 81% of neurons responded to somatostatin (300 nM) with an increase in K + conductance that reversed polarity at -114 mV. A greater proportion of somatostatin-sensitive neurons (93%) than somatostatin-insensitive neurons (53%) responded to the opioid agonist met-enkephalin (10 μM). Somatostatin also reduced the amplitude of evoked GABA A-mediated inhibitory postsynaptic currents (IPSCs). The actions of somatostatin in brain slices were mimicked by BIM-23027, but not by CH-275. Somatostatin had a variable effect on the rate of spontaneous miniature IPSCs in normal external potassium solutions. In high external potassium solutions, somatostatin reduced the rate of miniature IPSCs in all neurons, and this inhibition was abolished by addition of Cd 2+ (30 μM). Somatostatin had no effect on the amplitude of miniature IPSCs. These results indicate that somatostatin acts via sst-2 receptors to directly inhibit a subpopulation of PAG neurons by activating a potassium conductance and inhibits GABA release within PAG via a presynaptic Ca 2+-dependent mechanism. Thus, like opioids, somatostatin has the potential to exert pre- and postsynaptic disinhibitory effects within the PAG.

Original languageEnglish (US)
Pages (from-to)1273-1280
Number of pages8
JournalBritish Journal of Pharmacology
Volume142
Issue number8
DOIs
StatePublished - Aug 2004
Externally publishedYes

Fingerprint

Periaqueductal Gray
Somatostatin
Neurons
Inhibitory Postsynaptic Potentials
Potassium
L 362855
In Vitro Techniques
gamma-Aminobutyric Acid
Opioid Analgesics
Brain
Methionine Enkephalin
Mesencephalon
Analgesics

Keywords

  • Analgesia
  • Calcium current
  • Opioid
  • Periaqueductal grey
  • Potassium current
  • Somatostatin
  • Synaptic transmission

ASJC Scopus subject areas

  • Pharmacology

Cite this

Connor, M., Bagley, E. E., Mitchell, V. A., Ingram, S., Christie, M. J., Humphrey, P. P. A., & Vaughan, C. W. (2004). Cellular actions of somatostatin on rat periaqueductal grey neurons in vitro. British Journal of Pharmacology, 142(8), 1273-1280. https://doi.org/10.1038/sj.bjp.0705894

Cellular actions of somatostatin on rat periaqueductal grey neurons in vitro. / Connor, Mark; Bagley, Elena E.; Mitchell, Vanessa A.; Ingram, Susan; Christie, MacDonald J.; Humphrey, Patrick P A; Vaughan, Christopher W.

In: British Journal of Pharmacology, Vol. 142, No. 8, 08.2004, p. 1273-1280.

Research output: Contribution to journalArticle

Connor, M, Bagley, EE, Mitchell, VA, Ingram, S, Christie, MJ, Humphrey, PPA & Vaughan, CW 2004, 'Cellular actions of somatostatin on rat periaqueductal grey neurons in vitro', British Journal of Pharmacology, vol. 142, no. 8, pp. 1273-1280. https://doi.org/10.1038/sj.bjp.0705894
Connor, Mark ; Bagley, Elena E. ; Mitchell, Vanessa A. ; Ingram, Susan ; Christie, MacDonald J. ; Humphrey, Patrick P A ; Vaughan, Christopher W. / Cellular actions of somatostatin on rat periaqueductal grey neurons in vitro. In: British Journal of Pharmacology. 2004 ; Vol. 142, No. 8. pp. 1273-1280.
@article{04573e0a3c7344a29a3ea81f45fa90e2,
title = "Cellular actions of somatostatin on rat periaqueductal grey neurons in vitro",
abstract = "Functional studies indicate that the midbrain periaqueductal grey (PAG) is involved in the analgesic actions of somatostatin; however, the cellular actions of somatostatin in this brain region are unknown. In the present study, whole-cell patch clamp recordings were made from rat PAG neurons in vitro. In 93{\%} of acutely isolated neurons, somatostatin inhibited Ca 2+-channel currents. This effect was mimicked by the sst-2 selective agonist BIM-23027, but not by the sst-1 and sst-5 selective agonists CH-275 and L-362855. In brain slices, 81{\%} of neurons responded to somatostatin (300 nM) with an increase in K + conductance that reversed polarity at -114 mV. A greater proportion of somatostatin-sensitive neurons (93{\%}) than somatostatin-insensitive neurons (53{\%}) responded to the opioid agonist met-enkephalin (10 μM). Somatostatin also reduced the amplitude of evoked GABA A-mediated inhibitory postsynaptic currents (IPSCs). The actions of somatostatin in brain slices were mimicked by BIM-23027, but not by CH-275. Somatostatin had a variable effect on the rate of spontaneous miniature IPSCs in normal external potassium solutions. In high external potassium solutions, somatostatin reduced the rate of miniature IPSCs in all neurons, and this inhibition was abolished by addition of Cd 2+ (30 μM). Somatostatin had no effect on the amplitude of miniature IPSCs. These results indicate that somatostatin acts via sst-2 receptors to directly inhibit a subpopulation of PAG neurons by activating a potassium conductance and inhibits GABA release within PAG via a presynaptic Ca 2+-dependent mechanism. Thus, like opioids, somatostatin has the potential to exert pre- and postsynaptic disinhibitory effects within the PAG.",
keywords = "Analgesia, Calcium current, Opioid, Periaqueductal grey, Potassium current, Somatostatin, Synaptic transmission",
author = "Mark Connor and Bagley, {Elena E.} and Mitchell, {Vanessa A.} and Susan Ingram and Christie, {MacDonald J.} and Humphrey, {Patrick P A} and Vaughan, {Christopher W.}",
year = "2004",
month = "8",
doi = "10.1038/sj.bjp.0705894",
language = "English (US)",
volume = "142",
pages = "1273--1280",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Cellular actions of somatostatin on rat periaqueductal grey neurons in vitro

AU - Connor, Mark

AU - Bagley, Elena E.

AU - Mitchell, Vanessa A.

AU - Ingram, Susan

AU - Christie, MacDonald J.

AU - Humphrey, Patrick P A

AU - Vaughan, Christopher W.

PY - 2004/8

Y1 - 2004/8

N2 - Functional studies indicate that the midbrain periaqueductal grey (PAG) is involved in the analgesic actions of somatostatin; however, the cellular actions of somatostatin in this brain region are unknown. In the present study, whole-cell patch clamp recordings were made from rat PAG neurons in vitro. In 93% of acutely isolated neurons, somatostatin inhibited Ca 2+-channel currents. This effect was mimicked by the sst-2 selective agonist BIM-23027, but not by the sst-1 and sst-5 selective agonists CH-275 and L-362855. In brain slices, 81% of neurons responded to somatostatin (300 nM) with an increase in K + conductance that reversed polarity at -114 mV. A greater proportion of somatostatin-sensitive neurons (93%) than somatostatin-insensitive neurons (53%) responded to the opioid agonist met-enkephalin (10 μM). Somatostatin also reduced the amplitude of evoked GABA A-mediated inhibitory postsynaptic currents (IPSCs). The actions of somatostatin in brain slices were mimicked by BIM-23027, but not by CH-275. Somatostatin had a variable effect on the rate of spontaneous miniature IPSCs in normal external potassium solutions. In high external potassium solutions, somatostatin reduced the rate of miniature IPSCs in all neurons, and this inhibition was abolished by addition of Cd 2+ (30 μM). Somatostatin had no effect on the amplitude of miniature IPSCs. These results indicate that somatostatin acts via sst-2 receptors to directly inhibit a subpopulation of PAG neurons by activating a potassium conductance and inhibits GABA release within PAG via a presynaptic Ca 2+-dependent mechanism. Thus, like opioids, somatostatin has the potential to exert pre- and postsynaptic disinhibitory effects within the PAG.

AB - Functional studies indicate that the midbrain periaqueductal grey (PAG) is involved in the analgesic actions of somatostatin; however, the cellular actions of somatostatin in this brain region are unknown. In the present study, whole-cell patch clamp recordings were made from rat PAG neurons in vitro. In 93% of acutely isolated neurons, somatostatin inhibited Ca 2+-channel currents. This effect was mimicked by the sst-2 selective agonist BIM-23027, but not by the sst-1 and sst-5 selective agonists CH-275 and L-362855. In brain slices, 81% of neurons responded to somatostatin (300 nM) with an increase in K + conductance that reversed polarity at -114 mV. A greater proportion of somatostatin-sensitive neurons (93%) than somatostatin-insensitive neurons (53%) responded to the opioid agonist met-enkephalin (10 μM). Somatostatin also reduced the amplitude of evoked GABA A-mediated inhibitory postsynaptic currents (IPSCs). The actions of somatostatin in brain slices were mimicked by BIM-23027, but not by CH-275. Somatostatin had a variable effect on the rate of spontaneous miniature IPSCs in normal external potassium solutions. In high external potassium solutions, somatostatin reduced the rate of miniature IPSCs in all neurons, and this inhibition was abolished by addition of Cd 2+ (30 μM). Somatostatin had no effect on the amplitude of miniature IPSCs. These results indicate that somatostatin acts via sst-2 receptors to directly inhibit a subpopulation of PAG neurons by activating a potassium conductance and inhibits GABA release within PAG via a presynaptic Ca 2+-dependent mechanism. Thus, like opioids, somatostatin has the potential to exert pre- and postsynaptic disinhibitory effects within the PAG.

KW - Analgesia

KW - Calcium current

KW - Opioid

KW - Periaqueductal grey

KW - Potassium current

KW - Somatostatin

KW - Synaptic transmission

UR - http://www.scopus.com/inward/record.url?scp=4444321885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444321885&partnerID=8YFLogxK

U2 - 10.1038/sj.bjp.0705894

DO - 10.1038/sj.bjp.0705894

M3 - Article

VL - 142

SP - 1273

EP - 1280

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 8

ER -